携带顺式噬菌体基因组的M13噬菌体能够选择性地展示分子结构并传递治疗药物，且安全性良好。噬菌体展示技术在模拟抗原片段方面取得了突破，可以应用于抗体基础治疗，并有助于抗癌疫苗的设计。迄今为止，从使用M13噬菌体研发的创新生物传感器方面，进展显著，可以检测到生物特性、生物分子和人体细胞，并且有可接受的检测限值。针对耐药细菌的出现，M13噬菌体能够有效包装编程的基因编辑工具，如CRISPR/Cas，以靶向多个抗菌基因。此外，结合纳米颗粒的展示潜力激发了针对体内多个细胞生物标志物的靶向治疗平台的新方法。在本综述中，我们介绍了优化噬菌体应用的可用数据，重点关注至今为止关于M13噬菌体的经验，无论是作为单一药物或作为组合方案的一部分，应用于生物传感器、疫苗、细菌杀灭、特定抗原表位的模拟以及噬菌体引导纳米颗粒的药物传递系统。尽管研究兴趣日益增长，但我们需要对M13噬菌体的潜在生物学和遗传行为进行深入了解，以充分发挥这些生物因子在生物医学领域的潜力，正如本文所讨论的。我们还讨论了迄今为止限制M13噬菌体开发和实际推广的一些挑战。版权所有 © 2023. Elsevier Inc. 发表。

M13 phages possessing filamentous phage genomes offer the benefits of selective display of molecular moieties and delivery of therapeutic agent payloads with a tolerable safety profile. M13 phage-displayed technology for resembling antigen portions led to the discovery of mimetic epitopes that applied to antibody-based therapy and could be useful in the design of anticancer vaccines. To date, the excremental experiences have engaged the M13 phage in the development of innovative biosensors for detecting biospecies, biomolecules, and human cells with an acceptable limit of detection. Addressing the emergence of antibiotic-resistant bacteria, M13 phages are potent for packaging the programmed gene editing tools, such as CRISPR/Cas, to target multiple antimicrobial genes. Moreover, their display potential in combination with nanoparticles inspires new approaches for engineering targeted theragnostic platforms targeting multiple cellular biomarkers in vivo. In this review, we present the available data on optimizing the use of bacteriophages with a focus on the to date experiences with M13 phages, either as monoagent or as part of combination regimens in the practices of biosensors, vaccines, bactericidal, modeling of specific antigen epitopes, and phage-guided nanoparticles for drug delivery systems. Despite increasing research interest, a deep understanding of the underlying biological and genetic behaviors of M13 phages is needed to enable the full potential of these bioagents in biomedicine, as discussed here. We also discuss some of the challenges that have thus far limited the development and practical marketing of M13 phages.Copyright © 2023. Published by Elsevier Inc.